NCT06558981RecruitingPhase 3
Adjuvant Radiotherapy in High Risk Locally Advanced DTC
The Role of Adjuvant Radiotherapy in High Risk Locally Advanced Differentiated Thyroid Cancer：a 1:1 Randomized Phase III Clinical Trial
Source: ClinicalTrials.gov · Last updated 27 Feb 2026
Brief summary (registry, in English)
This study is a phase III randomized controlled clinical trial on the role of adjuvant radiotherapy in high-risk locally advanced differentiated thyroid cancer. Patients who meet the inclusion criteria were randomly assigned 1:1 to either the experimental group (adjuvant radiotherapy+RAI) or the control group (RAI), with LRFS as the primary endpoint of the study.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 124 (estimated)
- First submitted
- 26 Jul 2024
- Start date
- Jul 2024
- Primary completion date
- Jun 2031
- Lead sponsor
- Fudan University
- Diseases
- Thyroid cancer, Childhood cancers
- NCT number
- NCT06558981
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 124
- From Jul 2024 to the primary completion date, Jun 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously received radiation therapy for the head and neck area;
- Previously received 131I treatment;
- Previously received or currently receiving targeted therapy, immunotherapy, chemotherapy;
- Individuals with claustrophobia who are unable to undergo radiation therapy;
Other illness
- Differentiated thyroid cancer with poorly differentiated, or undifferentiated components;
- Within 5 years or simultaneously suffering from other active malignant tumors. Cured local tumors, such as skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, prostate carcinoma in situ, cervical carcinoma in situ, breast carcinoma in situ, can be included in the group;
- Other physical illnesses that affect patients' ability to receive standard treatment;
Lab values
- According to the researchers' assessment, there may be other factors that could force the subjects to terminate the study, such as suffering from other serious illnesses (including mental illnesses) that require concurrent treatment, severe abnormal laboratory test values, family or social factors that may affect the safety of the subjects or the collection of experimental data;
Other
- There is distant metastasis;
- Pregnant or lactating women;
- Patients deemed unsuitable for inclusion by other attending physicians.
Who the study is looking for
- The patient voluntarily joined this study and signed an informed consent form;
- Age: ≥ 14 years old,\<80 years old, male or female not limited;
- Histopathological diagnosis of differentiated thyroid cancer;
- Surgical total or near total thyroidectomy;
- The surgery did not achieve R0 resection, and R1/ R2 resection was performed. The volume of residual tumor in R2 resected patients is less than 2cm3;
- The main organ functions are normal;
- Good compliance and cooperation with follow-up.
Age in the registry: 14 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fudan Univeristy Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.